Healios
Cell Therapy Development, Regenerative Medicine & Cell Materials · Minato, Tokyo
Healios develops cell-therapy and regenerative-medicine candidates. Its bone-marrow-derived somatic stem-cell program HLCM051 covers acute respiratory distress syndrome, ischemic stroke and trauma. Cancer research uses gene-edited iPS-cell-derived natural killer cells, with Akatsuki Therapeutics leading that development program.
Its Universal Donor Cell platform uses gene editing to develop iPS cells intended to reduce the risk of immune rejection. Research is based at the Kobe Research Institute, and the company is also developing a materials business selling culture supernatant obtained during cell manufacturing. Healios had 82 employees as of June 2026.
0
open positions at Healios
No live listings from Healios right now — browse all Tokyo software jobs instead.